A Randomized Controlled, Phase 2 Trial of the Viral Serpin Serp-1 in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

Authors :: Tardif, Jean-Claude
L'Allier, Philippe L.
Gregoire, Jean
Ibrahim, Reda
McFadden, Grant
Kostuk, William
Knudtson, Merril
Labinaz, Marino
Waksman, Ron
Pepine, Carl J.
Macaulay, Colin
Guertin, Marie-Claude
Lucas, Alexandra
Source :: Circulation: Cardiovascular Interventions; Dec2010, Vol. 3 Issue 6, p543-548, 6p, 1 Diagram, 3 Charts, 2 Graphs
Publication Year :: 2010
Abstract: The article discusses a study which investigated the safety and efficacy of Serp-1 in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention. The study found that key safety outcomes such as coagulation parameters and adverse events did not differ between Serp-1 and placebo groups. It concludes that the reduction in myocardial damage biomarkers supports further assessment of Serp-1 in ACS patients.

Subjects :: ACUTE coronary syndrome
SERPINS
BIOMARKERS
PATIENTS
PLACEBOS
DISEASES

Full Text Access

Tools